Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...
Newsner on MSN
John Tesh shares emotional cancer update after being told he had only 18 months to live
The iconic former Entertainment Tonight host John Tesh, 73, was told that he might have only 18 months to live after he was diagnosed with cancer in 2015. Now, a little more than a decade later, he ...
A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...
Thirty-six progressive mCRPC patients received TLX591-Tx across three cohorts (enzalutamide, abiraterone, or docetaxel sequence), and all completed two planned doses without emergent, unexpected ...
News-Medical.Net on MSN
Low baseline testosterone predicts aggressive prostate cancer progression risk
A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results